Grad 3 - eller Grad 4- trombocytabnormaliteter, inklusive trombocytopeni- bivirkninger blev set hos 14% af patienterne, der fik TMZ.
Grade 3 or Grade 4 thrombocyte abnormalities, including thrombocytopenic events were observed in 14% of the patients who received TMZ.